Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Akumin Inc AKUMQ

Akumin Inc. is a provider of radiology and oncology services to health systems, hospitals, physician groups, and patients all across the country. The Company operates through two segments: Radiology and Oncology. The Company provides fixed-site outpatient diagnostic imaging services through a network of approximately 180 owned and/or operated imaging locations, and outpatient radiology and oncology services and solutions to approximately 1,000 hospitals and health systems across 48 states. Its imaging procedures include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography and other related procedures. Its cancer care services include a full suite of radiation therapy and related offerings. Its services include radiology exams, radiology technology, radiology subspecialties, oncology conditions treated and oncology radiation therapy.


OTCPK:AKUMQ - Post by User

Post by davgroon Aug 16, 2022 6:35pm
381 Views
Post# 34900736

There’s a ton of upside to Akumin (AKU), says Clarus

There’s a ton of upside to Akumin (AKU), says Clarus
By Jayson MacLean 
Published on August 16, 2022

It’s a good time to be buying US healthcare stock Akumin Inc. (NASDAQ:AKU), according to Clarus Securities analyst Noel Atkinson. Akumin is down about 68 per cent over the past 12 months, but a new cash injection has Atkinson raising his target price on Monday from $6.50 to $6.75 per share, good for a projected return of 777 per cent at the time of publication.

Continue reading at link below:

https://www.cantechletter.com/2022/08/theres-a-ton-of-upside-to-akumin-says-clarus/
<< Previous
Bullboard Posts
Next >>